Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials

Neurotoxicity is an off-tumour, on-target side effect of GD2-directed immunotherapy with monoclonal antibodies. Here, we report the frequency, management and outcome of patients enrolled in two prospective clinical trials who experienced severe neurotoxicity during immunotherapy with the anti-GD2 an...

Full description

Bibliographic Details
Main Authors: Fiedler, S. (Author), Garaventa, A. (Author), Gray, J. (Author), Ladenstein, R. (Author), Lode, H.N (Author), Manzitti, C. (Author), Papadakis, V. (Author), Poetschger, U. (Author), Pribill, I. (Author), Valteau-Couanet, D. (Author), Wieczorek, A. (Author), Zachwieja, K. (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
anti-GD2 antibody
dinutuximab beta
neuroblastoma
neurotoxicity
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items